TauRx Pharmaceuticals Ltd: Tau-targeting Alzheimer's treatme

TauRx Pharmaceuticals Ltd: Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial

LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published researchSafety profile

Related Keywords

Malaysia , United Kingdom , Singapore , Kostenloser Wertpapierhandel , Claude Wischik , Genting Taurx Diagnostic Centre Sdn Bhd , Gt Diagnostics United Kingdom , Global Conference Of Alzheimer Disease International , University Of Aberdeen , Taurx Pharmaceuticals Ltd Group , Regulatory Agency , Genting Berhad , Taurx Therapeutics Ltd , Taurx Pharmaceuticals Ltd , Executive Chairman , Global Conference , United Kingdom Medicines , Innovation Passport , Innovative Licensing , Access Pathway , Mild Cognitive Impairment , Taurx Diagnostic Centre Sdn Bhd , Taurx , Pharmaceuticals , Targeting , Lzheimer , Treatment , Imtm , Moving , Howard , Egulatory , Submission , Ased , Nitial , Data , Rom , Lucidity , Trial ,